شناسایی و اولویت‌بندی فرایندهای مدیریت زنجیره تأمین مؤثر بر مزیت‌ رقابتی در شرکت داروسازی ثامن

[1] A. Szmelter, “Global pharmaceutical industry: Characteristics and trends,” In Global Supply Chains in the Pharmaceutical Industry. IGI Global Scientific Publishing. pp. 57-85, 2019. DOI:10.4018/978-1-5225-5921-4.ch003

[2] Q. Zhang, M. Huang, X. Huang, L. Gan, Y. Li, and H. Huang, “Study on the factors affecting the competitiveness of biopharmaceutical industry cluster: Evidence from Guangdong and Zhejiang of China,” J. Holistic Integr. Pharm., vol. 6, no. 1, pp. 117-123, 2025. https://doi.org/10.1016/j.jhip.2025.03.004

[3] M. Haghgoo, and A. Khaleghi, “Survey and Analysis of the Pharmaceutical Industry,” Retrieved 21 November 2025 from https://tsemag.ir. [In Persian].

[4] D. Kesič, “Strategic analysis of the world pharmaceutical industry,” MANAG-J CONTEMP MANA, vol. 14, no. 1, pp. 59-76, 2009.

[5] K. F. Huang, R. Dyerson, L. Y. Wu, and G. Harindranath, “From temporary competitive advantage to sustainable competitive advantage,” Br. J. Manag., vol. 26, no. 4, pp. 617-636, 2015. https://doi.org/10.1111/1467-8551.12104

[6] L. S. Keong, and O. Dastane, “Building a sustainable competitive advantage for Multi-Level Marketing (MLM) firms: An empirical investigation of contributing factors,” J. Distrib. Sci., vol. 17, no. 3, pp. 5-19, 2019. http://dx.doi.org/10.15722/jds.17.03.201903.5

[7] A. B. Elijah, and A. D. Millicent, “The impact of a sustainable competitive advantage on a firm’s performance: Empirical evidence from Coca-Cola Ghana limited,” Glob. J. Hum. Resour. Manag., vol. 6, no. 5, pp. 30-46, 2018.

[8] V. P. Economou, and P. G. Chatzikonstantinou, “Gaining company’s sustained competitive advantage, is really a necessary precondition for improved organizational performance? The case of TQM,” Eur. Res. Stud., vol. XII, no. 3, pp. 83-100, 2009. DOI: 10.35808/ersj/233

[9] E. S. Knudsen, L. B. Lien, B. Timmermans, I. Belik, and S. Pandey, “Stability in turbulent times? The effect of digitalization on the sustainability of competitive advantage,” J. Bus. Res., vol. 128, pp. 360-369, 2021. https://doi.org/10.1016/j.jbusres.2021.02.008

[10] B. Ivens, K. Kasper-Brauer, A. Leischnig, and S. C. Thornton, “Implementing customer relationship management successfully: A configurational perspective,” Technol. Forecast. Soc. Change., vol. 199, pp. 123083, 2024. https://doi.org/10.1016/j.techfore.2023.123083

[11] L. Peters, B. S. Ivens, and C. Pardo, “Key account managers' identification profiles and effectiveness: A fuzzy-set qualitative comparative analysis,” Ind. Mark. Manag., vol. 107, pp. 253-265, 2022. https://doi.org/10.1016/j.indmarman.2022.09.022

[12] B. S. Ivens, A. Leischnig, C. Pardo, and B. Niersbach, “Key account management as a firm capability,” Ind. Mark. Manag., vol. 74, pp. 39-49, 2018. https://doi.org/10.1016/j.indmarman.2017.09.026

[13] M. Khodad Hoseini, and S. Asghari, “Investigating the effect of human capital on competitive advantage with regard to the mediating role of market measurement capability and brand management capability and the moderating role of market dynamics (Case study: Iran Insurance Company branches in Mashhad),” Master's Thesis, Kheradgarayan Motahhar Institute of Higher Education, Mashhad, 2019. [In Persian].

[14] A. Dashti, H. Bastam, and M. Omrani, “Identifying and ranking factors influencing the occurrence of conflict in the distribution network (Case study: Mashhad broadcasting companies),” Master's Thesis, Tabaran Institute of Higher Education, Mashhad, 2019. [In Persian].

[15] T. Shi, D. Chhajed, Z. Wan, and Y. Liu, “Distribution channel choice and divisional conflict in remanufacturing operations,” Prod. Oper. Manag., vol. 29, no. 7, pp. 1702-1719, 2020. https://doi.org/10.1111/poms.13185

[16] A. Abedini, H. Irani, and H. Yazdani, “Identify and Prioritize the Critical Success Factors in Pharmaceutical Supply Chain and Distribution Using the DEMETEL Technique,” J. Payavard Salamat., Tehran University of Medical Sciences (Health Outcomes), vol. 13, no. 1, pp. 45-59, 2019. [In Persian].

[17] M. Soleimani Sedehi, and N. Ghafari Nasab, “Supply Chain Management (Process Reference Models, Performance and Software Indicators),” Tehran: Institute for Trade Studies and Research Publications, 2013. [In Persian].

[18] M. R. Y. Zeebaree, and R. B. Siron, “The impact of entrepreneurial orientation on competitive advantage moderated by financing support in SMEs,” Int. Rev. Manag. Mark., vol. 7, no. 1, pp. 43-52, 2017.

[19] S. L. Newbert, “Value, rareness, competitive advantage, and performance: A conceptual‐level empirical investigation of the resource‐based view of the firm,” Strateg. Manag. J., vol. 29, no. 7, pp. 745-768, 2008. https://doi.org/10.1002/smj.686

[20] R. Makadok, “Toward a synthesis of the resource‐based and dynamic‐capability views of rent creation,” Strateg. Manag. J., vol. 22, no. 5, pp. 387-401, 2001. https://doi.org/10.1002/smj.158

[21] J. K. Sharma, and A. K. Singh, “Absorptive capability and competitive advantage: Some insights from Indian pharmaceutical industry,” Int. J. Manag. Bus. Res., vol. 2, no. 3, pp. 175-192, 2012.

[22] N. D. Nte, K. N. Omede, B. K. Enokie, and O. Bienose, “Competitive intelligence and competitive advantage in pharmaceutical firms in developing economies: A review of Lagos state, Nigeria,” Journal of Management, Economics, and Industrial Organization, vol. 4, no. 1, pp. 76-99, 2020. DOI:10.31039/jomeino.2020.4.1.5

[23] M. Takayama, C. Watanabe, and C. Griffy-Brown, “Alliance strategy as a competitive strategy for successively creative new product development: The proof of the co-evolution of creativity and efficiency in the Japanese pharmaceutical industry,” Technovation, vol. 22, no. 10, pp. 607-614, 2002. https://doi.org/10.1016/S0166-4972(01)00062-1

[24] H. C. Huang, M. C. Lai, and L. H. Lin, “Developing strategic measurement and improvement for the biopharmaceutical firm using the BSC hierarchy,” Expert Syst. Appl., vol. 38, no. 5, pp. 4875-4881, 2011. https://doi.org/10.1016/j.eswa.2010.09.069

[25] M. Takayama, C. Watanabe, and C. Griffy-Brown, “Remaining innovative without sacrificing stability: An analysis of strategies in the Japanese pharmaceutical industry that enable firms to overcome inertia resulting from successful market penetration of new product development,” Technovation, vol. 22, no. 12, pp. 747-759, 2002. https://doi.org/10.1016/S0166-4972(01)00067-0

[26] A. F. Cortes, and P. Herrmann, “Strategic leadership of innovation: A framework for future research,” Int. J. Manag. Rev., vol. 23, no. 2, pp. 224-243, 2021. https://doi.org/10.1111/ijmr.12246

[27] Y. Zhang, U. Khan, S. Lee, and M. Salik, “The influence of management innovation and technological innovation on organization performance: A mediating role of sustainability.” Sustainability, vol. 11, no. 2, pp. 495, 2019. https://doi.org/10.3390/su11020495

[28] A. H. Pratono, and L. Han, “From family business orientation to organisational citizenship behaviour: Prosocial behaviour in family business performance,” J. Fam. Bus. Manag., vol. 12, no. 4, pp. 923-937, 2022. https://doi.org/10.1108/JFBM-02-2021-0014

[29] S. Hendrayanti, “Build competitive advantage to improve company performance,” Manag. Anal. J., vol. 11, no. 3, pp. 274-280, 2022. DOI 10.15294/MAJ.V11I3.59649

[30] M. N. K. Niwash, K. Cek, and S. Z. Eyupoglu, “Intellectual capital and competitive advantage and the mediation effect of innovation quality and speed, and business intelligence,” Sustainability, vol. 14, no. 6, pp. 3497, 2022. DOI:10.3390/su14063497

[31] M. Mohammadian Mahmoudi Tabar, and N. Javani, “The relationship between sustainable competitive advantage and key success factors in the pharmaceutical industry,” First International Conference on Management and Industry, Tbilisi, 1400. [In Persian].

[32] D. Karakabadi, and A. Tayyebi Rahani, “Identifying and Prioritizeing Supply Chain Digitization Barriers Using the ISM Approach,” J. Supply Chain Manag., vol. 27, no. 87, pp. 1-18, 1404. [In Persian]. DOR: 20.1001.1.20089198.1404.27.87.1.5

[33] S. Arbabi, H. A. Sadeghi, and H. Golpira, “Sustainable Construction Supply Chain Management with Stochastic Material Demand,” J. Supply Chain Manag., vol. 28, no. 87, pp. 19-37, 1404. [In Persian]. DOR: 20.1001.1.20089198.1404.27.87.2.6

[34] R. B. Handfield, and E. L. Nichols Jr., “Introduction to Supply Chain Management,” Pearson India, 2015.

[35] M. D. A. R. Al-Shboul, K. D. Barber, J. A. Garza-Reyes, V. Kumar, and M. R. Abdi, “The effect of supply chain management practices on supply chain and manufacturing firms’ performance,” J. Manuf. Technol. Manag., vol. 28, no. 5, pp. 577-609, 2017. DOI:10.1108/JMTM-11-2016-0154

[36] A. Ehsani, and A. E. Zahedi, “Investigating the Impact of Sustainability and Resilience on Supply Chain Performance in Affiliated Companies of the Iranian Automotive Industry,” J. Supply Chain Manag., vol. 27, no. 86, pp. 1-17, 1404. [In Persian]. DOR: 20.1001.1.20089198.1404.27.86.1.3

[37] L. S. Cook, D. R. Heiser, and K. Sengupta, “The moderating effect of supply chain role on the relationship between supply chain practices and performance: An empirical analysis,”        Int. J. Phys. Distrib. Logist. Manag., vol. 41, no. 2, pp. 104-134, 2011. DOI:10.1108/09600031111118521

[38] C. M. Sashi, “Conflict resolution strategies and marketing channel relationships: Framework and research propositions,” Journal of Global Business Management, vol. 5, no. 1, pp. 63-169, 2009.

[39] G. Mehralian, A. Rajabzadeh, M. Reza Sadeh, and H. Reza Rasekh, “Intellectual capital and corporate performance in Iranian pharmaceutical industry,” J. Intellect. Cap., vol. 13, no. 1, pp. 138-158, 2012. DOI:10.1108/14691931211196259

[40] A. Azar, and A. Khorami, “Designing a supply chain agility model in the pharmaceutical industry using Interpretive Structural Modeling (ISM) approach,” Public Management Research, vol. 14, no. 53, pp. 29-63, 2011. [In Persian]. 10.22111/JMR.2021.34316.5081

[41] M. Haji Babaei, and J. Behnamian, “Two-stage stochastic programming for designing a real-time pharmaceutical supply chain network: Modeling and solution algorithm,” Ind Manag Persp, vol. 11, no. 4, pp. 137-165, 2011. [In Persian]. 10.52547/JIMP.11.4.137

[42] G. Mehralian, F. Zarenezhad, and A. Rajabzadeh Ghatari, “Developing a model for an agile supply chain in pharmaceutical industry,” Int. J. Pharm. Healthc. Mark., vol. 9, no. 1, pp. 74-91, 2015. https://doi.org/10.1108/IJPHM-09-2013-0050

[43] A. Jafarnejad, and M. Mahmoudi, “Sustainable Supply Chain,” Tehran: Ketab Mehraban Nashr, 2015. [In Persian].

[44] I. Shaygan, J. Bamdad Sofi, A. Kazazi, and M. Taghavifard, “Designing and explanation of a model based on large supply chain strategy to improve competitive performance in the Iranian pharmaceutical industry (generic drug production),” C4I Journal, 6(1), 31-52, 1401. [In Persian].

[45] S. A. Narayana, R. K. Pati, and P. Vrat, “Managerial research on the pharmaceutical supply chain-A critical review and some insights for future directions,” J PURCH SUPPLY MANAG., vol. 20, no. 1, pp. 18-40, 2014. https://doi.org/10.1016/j.pursup.2013.09.001

[46] T. Zhou, and G. K. Getele, “Determinants of competitive advantage through achieving pharmaceutical supply chain management capabilities in the Ethiopian healthcare sector,” J. Health Organ. Manag., 2025. https://doi.org/10.1108/JHOM-04-2024-0136

[47] W. P. Wong, P. S. Saw, S. Jomthanachai, L. S. Wang, H. F. Ong, and C. P. Lim, “Digitalization enhancement in the pharmaceutical supply network using a supply chain risk management approach,” Sci. Rep., vol. 13, no. 1, pp. 22287, 2023. DOI:10.1038/s41598-023-49606-z

[48] M. Büssgen, and M. A. Büssgen, “Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades,” J. Pharm. Policy Pract., vol. 16, no. 1, pp. 109, 2023. DOI:10.1186/s40545-023-00612-6

[49] E. Kourtis, M. Kourtis, P. Curtis, and M. Hanias, “Sustainable business growth, value creation and dynamic competitive advantage: The Greek pharmaceutical industry,” Eur. Res. Stud., vol. XXV, no. 2, pp. 46-79, 2022. DOI:10.35808/ersj/2906

[50] A. A. A. Sharabati, S. A. Al-Atrash, and I. Y. Dalbah, “The use of supply chain control tower in pharmaceutical industry to create a competitive advantage,” Int. J. Pharm. Healthc. Mark., vol. 16, no. 3, pp. 354-375, 2022. https://doi.org/10.1108/IJPHM-08-2020-0064

[51] A. A. A. Sharabati, “Green supply chain management and competitive advantage of Jordanian pharmaceutical industry,” Sustainability, vol. 13, no. 23, pp. 13315, 2021. DOI:10.3390/su132313315

[52] G. B. Ünal, “The Role of Product Innovation in The Pharmaceutical Industry, Its Effect On Competitiveness,” PhD Thesis, Near East University, Cyprus, 2021.

[53] H. Zghoul, and S. Al-Haddad, “The influence of product innovation on customer satisfaction in the pharmaceutical sector in Jordan,” International Journal of Applied Research on Public Health Management (IJARPHM), vol. 6, no. 1, pp. 45-63, 2021. DOI:10.4018/IJARPHM.2021010104

[54] M. Papalexi, D. Bamford, and L. Breen, “Key sources of operational inefficiency in the pharmaceutical supply chain,” SUPPLY CHAIN MANAG., vol. 25, no. 6, pp. 617-635, 2020. DOI:10.1108/SCM-02-2019-0076

[55] D. Kapoor, R. B. Vyas, and D. Dadarwal, “An overview on pharmaceutical supply chain: A next step towards good manufacturing practice,” Drug Designing & Intellectual Properties International Journal, vol. 1, no. 2, pp. 49-54, 2018. DOI:10.32474/DDIPIJ.2018.01.000107

[56] G. Balestra, “Strategic Product Portfolio Management: A Focus on the Bio-Pharmaceutical Sector and Roche,” Master's Thesis, Universitá Guido Carli, Italy, 2017.

[57] A. M. N. Francisquinho, “Consumer Attitudes and Perceptions Towards Medicine Types: Brand Medicines Versus Generic Medicines,” Master's Thesis, ISCTE-Instituto Universitario de Lisboa, Portugal, 2013.

[58] M., Yousefi Sarmad, M. S. Pishvaee, H. Jahani, S. M. S. Khaksar, and D. Ivanov, “Integrated planning for a global pharmaceutical supply chain: An ambidexterity perspective,” Ann. Oper. Res., vol. 346, no. 2, pp. 1717-1766, 2025. https://doi.org/10.1007/s10479-023-05554-5

[59] S. George, and S. Elrashid, “Inventory management and pharmaceutical supply chain performance of hospital pharmacies in Bahrain: A structural equation modeling approach,” Sage Open, vol. 13, no. 1, pp. 21582440221149717, 2023. DOI:10.1177/21582440221149717

[60] A. Laghouag, The maturity of sustainable supply chain management practices: An applied study on pharmaceutical firms,” Journal of Money and Business, vol. 3, no. 2, pp. 237-249, 2023. DOI:10.1108/JMB-06-2023-0033

[61] F. Kaupa, and M. J. Naude, “Barriers in the supply chain management of essential medicines in the public healthcare system in Malawi,” Afr. J. Gov. Dev., vol. 10, no. 1, pp. 34-60, 2021.

[62] D. Weraikat, M. K. Zanjani, and N. Lehoux, “Improving sustainability in a two-level pharmaceutical supply chain through vendor-managed inventory system,” Oper. Res. Health Care., vol. 21, pp. 44-55, 2019. https://doi.org/10.1016/j.orhc.2019.04.004

[63] M. A. Moktadir, S. M. Ali, S. K. Mangla, T. A. Sharmy, S. Luthra, , N. Mishra, and J. A. Garza-Reyes, “Decision modeling of risks in pharmaceutical supply chains,” Ind. Manag. Data Syst., vol. 118, no. 7, pp. 1388-1412, 2018. DOI:10.1108/IMDS-10-2017-0465

[64] R. K. Singh, R. Kumar, and P. Kumar, “Strategic issues in pharmaceutical supply chains: A review,” Int. J. Pharm. Healthc. Mark., vol. 10, no. 3, pp. 234-257, 2016. DOI:10.1108/IJPHM-10-2015-0050

[65] Y. H. Lin, K. M. Tsai, W. J. Shiang, T. C. Kuo, and C. H. Tsai, “Research on using ANP to establish a performance assessment model for business intelligence systems,” Expert Syst. Appl., vol. 36, no. 2, pp. 4135-4146, 2009. https://doi.org/10.1016/j.eswa.2008.03.004

[66] C. H. Lawshe, “A quantitative approach to content validity,” Pers. Psychol., vol. 28, no. 4, pp. 563-575, 1975.

[67] B. A. Chadwick, H. M. Bahr, and S. L. Albrecht, “Social Science Research Methods,” Englewood Cliffs, NJ: Prentice-Hall, 1984.

[68] T. L. Saaty, “Decision making with the analytic hierarchy process,” Int. J. Serv. Sci., vol. 1, no. 1, pp. 83-98, 2008.

[69] T. L. Saaty, “The Analytic Hierarchy Process,” McGraw-Hill, New York, 1980.

[70] R. S. Kaplan, and D. P. Norton, “Strategy Maps: Converting Intangible Assets into Tangible Outcomes,” Harvard Business Press, 2003.

[71] M. Lashkar-e-Blouki, “Techniques and Commandments of Strategic Thinking,” Tehran: Nass Scientific and Cultural Institute Publications, 1402. [In Persian].

[72] T. H. H. Bui, A. D. Hoang, and Y. T.  Kim, “An application of full analytic hierarchy process to identify the best use of Dong Ngo closed‐landfill site in Bac Ninh city, Vietnam,” Environ. Prog. Sustain. Energy., vol. 38, no. 6, pp. e13273, 2019. DOI:10.1002/ep.13273

[73] A. Amini, “Analysis of the effect of technological intelligence on enterprise competitive advantage (case study: pharmaceutical companies),” Journal of Healthcare Management Research (JHMR), vol. 8, no. 2, pp. 75-85, 2016. [In Persian].

[74] L. Garattini, and A. Padula. “Competition in pharmaceuticals: More product-than price-oriented?,” Eur. J. Health Econ., vol. 19, no. 1, pp. 1-4, 2018. DOI: 10.1007/s10198-017-0932-4

[75] B. Piachaud, “Outsourcing of R&D in the Pharmaceutical Industry: From Conceptualization to Implementation of the Strategic Sourcing Process,” Springer, 2004. 10.1057/9780230512634

[76] M. Bahraini Zadeh, and M. Haraghi, “Investigating brand equity in the pharmaceutical industry,” The Second International Conference on Management, Entrepreneurship and Economic Development, Qom, 2012. [In Persian].

[77] M. Bashirynejad, F. Soleymani, S. Nikfar, A. Kebriaeezadeh, R. Majdzadeh, B. Fatemi, A. Zackery, and N. Zare, “Trends analysis and future study of the pharmaceutical industry field: A scoping review,” DARU J. Pharm. Sci., vol. 33, no. 1, pp. 6, 2024. DOI:10.1007/s40199-024-00550-x

[78] S. N. Mousavi, A. Ghafourian Shagerdi, and A. Shariatnejad, “Improving the competitiveness of pharmaceutical companies; Explaining solutions to increase the share of the drug consumption market,” Consumer Behavior Studies Journal, vol. 8, no. 3, pp. 57-78, 2021. [In Persian]. 20.1001.1.27170004.1400.8.3.2.5

[79] M. Javidan, “Core competence: What does it mean in practice?,” Long Range Plann, vol. 31, no. 1, pp. 60-71, 1998. https://doi.org/10.1016/s0024-6301(97)00091-5

[80] O. C. Walker, Jr., J. W. Mullins, “Marketing Strategy: A Decision-Focused Approach,” McGraw-Hill, Irwin, 2014. [In Persian].

[81] R. Mohtaram, and R. Nasiri Savadkouhi, “International Business: Theories and Applications,” Tehran: Business Publishing Company, 2019. [In Persian].